Summaries of health policy coverage from major news organizations
FDA Approves Roche’s New Invirase Formulation
FDA on Monday approved a new formulation for the protease inhibitor Invirase, which is manufactured by Swiss-based pharmaceutical company Roche, Reuters reports (Reuters, 12/20). The new 500 mg Invirase tablets will decrease patients' pill burden from 10 pills daily to four daily. The tablets also are smaller in size than the current 200 mg capsules and are made to be used in a regimen of 1000 mg Invirase with 100 mg ritonavir as a "booster" (Kaiser Daily HIV/AIDS Report, 6/23). "With the new Invirase 500 mg tablet now available, pill burden is considerably reduced and we anticipate that this improved convenience together with 'boosted' Invirase's record of convincing data will result in an expansion of its use in the earlier stages of HIV therapy," William Burns, head of Roche's pharmaceutical division, said (Roche release, 12/20).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.